Telix H1 Revenue Jumps 22% to $477M, EBITDA Up 146%, Regeneron Deal Adds $40M
TLX sits 95% above its 52-week low of $6.28.
Summary
Telix reported H1 2026 revenue of $477M, up 22% year-over-year, with adjusted EBITDA of $52M, up 146%. The company reaffirmed FY 2026 revenue guidance of $950M-$970M plus $40M other income from a new Regeneron collaboration. Profit after tax was $38M, including the $40M Regeneron payment and $19M finance costs from refinancing $600M of convertible bonds. The company also established an at-the-market equity facility with Morgan Stanley and William Blair, providing optionality for future capital raises. Key pipeline milestones include FDA alignment on ProstACT Global Part 2 and a PDUFA date of September 11, 2026 for Pixclara. The stock is trading near its 52-week high, reflecting strong commercial execution and late-stage pipeline momentum.
At the time of this announcement, TLX was trading at $12.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $6.28 to $12.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.